Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90.
暂无分享,去创建一个
Briana Foley | Laura G. Dubois | Philip F. Hughes | Laura G Dubois | T. Haystead | J. Veal | P. Fadden | S. Hall | K. Verleysen | Anisa Scott | John Rice | Philip F Hughes | Gunnar J Hanson | G. Hanson | Wei-Ping Ma | Patrick Fadden | Kenneth H Huang | James M Veal | Paul M Steed | Amy F Barabasz | Mei Hu | Jeffrey M Partridge | Tiffany A Freed | Melanie A Rehder Silinski | Thomas E Barta | Andy Ommen | Wei Ma | Emilie D Smith | Angela Woodward Spangenberg | Jeron Eaves | Lindsay Hinkley | Matthew Jenks | Meredith Lewis | James Otto | Gijsbertus J Pronk | Katleen Verleysen | Timothy A Haystead | Steven E Hall | Lindsay Hinkley | P. Steed | M. Hu | J. M. Partridge | G. Pronk | K. Huang | J. Eaves | A. Barabasz | Briana E. Foley | T. Barta | Melanie A Silinski | Anisa Scott | T. Freed | Andy J. Ommen | E. D. Smith | M. Jenks | M. Lewis | J. Otto | J. Rice
[1] James S. Duncan,et al. An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics , 2008, Molecular & Cellular Proteomics.
[2] Gabriela Chiosis,et al. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. , 2006, Journal of medicinal chemistry.
[3] N. Rosen,et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. , 2004, Chemistry & biology.
[4] Timothy A J Haystead,et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. , 2002, Molecular pharmacology.
[5] L. Pearl,et al. Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.
[6] Cathy H. Wu,et al. The Universal Protein Resource (UniProt) , 2004, Nucleic Acids Res..
[7] W. Pratt,et al. Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1 , 2003, Experimental biology and medicine.
[8] S. Lindquist,et al. HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.
[9] F. Hartl,et al. In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis , 1998, The Journal of cell biology.
[10] F Gharahdaghi,et al. Mass spectrometric identification of proteins from silver‐stained polyacrylamide gel: A method for the removal of silver ions to enhance sensitivity , 1999, Electrophoresis.
[11] E. De Clercq,et al. Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects. , 2006, Journal of Medicinal Chemistry.
[12] T. Sørensen,et al. A method of establishing group of equal amplitude in plant sociobiology based on similarity of species content and its application to analyses of the vegetation on Danish commons , 1948 .
[13] D. Solit,et al. Hsp90: the vulnerable chaperone. , 2004, Drug discovery today.
[14] U. Banerji,et al. Heat Shock Protein 90 as a Drug Target: Some Like It Hot , 2009, Clinical Cancer Research.
[15] L. Neckers,et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[16] Sarat Chandarlapaty,et al. SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers , 2008, Clinical Cancer Research.
[17] L. Neckers,et al. Heat shock protein 90: The cancer chaperone , 2007, Journal of Biosciences.
[18] Paul Workman,et al. Inhibitors of the heat shock response: Biology and pharmacology , 2007, FEBS letters.
[19] L. Pearl,et al. Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone , 1997, Cell.
[20] A. King,et al. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[21] X. Barril,et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. , 2004, Chemistry & biology.
[22] Y. Janin. Heat Shock Protein 90 Inhibitors. A Text Book Example of Medicinal Chemistry , 2006 .
[23] L. Holm,et al. The Pfam protein families database , 2005, Nucleic Acids Res..
[24] T. Haystead. The purinome, a complex mix of drug and toxicity targets. , 2006, Current topics in medicinal chemistry.
[25] Robert D. Finn,et al. The Pfam protein families database , 2004, Nucleic Acids Res..
[26] J. Deisenhofer,et al. Synapsin I is structurally similar to ATP‐utilizing enzymes , 1998, The EMBO journal.
[27] Xavier Barril,et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. , 2005, Journal of medicinal chemistry.
[28] J. Veal,et al. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. , 2008, Bioorganic & medicinal chemistry letters.
[29] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[30] Laura G. Dubois,et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. , 2009, Journal of medicinal chemistry.
[31] Helge Weissig,et al. Functional interrogation of the kinome using nucleotide acyl phosphates. , 2007, Biochemistry.
[32] L. Pearl,et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.
[33] H. J. Harwood. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome. , 2004, Current opinion in investigational drugs.
[34] P Ferrara,et al. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. , 1992, Analytical biochemistry.
[35] D. Sawyer,et al. Heat shock proteins in cancer: chaperones of tumorigenesis. , 2006, Trends in biochemical sciences.
[36] S. Kasibhatla,et al. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. , 2007, Journal of medicinal chemistry.
[37] L. Neckers,et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. , 1998, Cell stress & chaperones.
[38] Sreenath V. Sharma,et al. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol , 1998, Oncogene.
[39] L. Pearl,et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo , 1998, The EMBO journal.
[40] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] D. Solit,et al. Development and application of Hsp90 inhibitors. , 2008, Drug discovery today.
[42] Neal Rosen,et al. Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.
[43] Mike Wood,et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.